Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia
Raniah I Alnaser1,2, Fawaz A Alassaf2, Mohammed N Abed3
1Nineveh Health Directorate, Mosul, Iraq.
Background:
Recent studies have linked sarcopenia development to the hallmarks of diabetes, oxidative stress, and insulin resistance. The anti-oxidant and insulin sensitivityenhancing effects of incretin-based therapies may provide a promising option for the treatment of sarcopenia. This review aimed to unveil the role of oxidative stress and insulin resistance in the pathogenesis of sarcopenia and explore the potential benefits of incretin-based therapies in individuals with sarcopenia.
Methods:
PubMed, the Cochrane Library, and Google Scholar databases were searched by applying keywords relevant to the main topic, to identify articles that met our selection criteria.
Results:
Incretin-based therapies manifested anti-oxidant effects by increasing the anti-oxidant defense system and decreasing free radical generation or by indirectly minimizing glucotoxicity, which was mainly achieved by improving insulin signaling and glucose homeostasis. Likewise, these drugs exhibit insulin-sensitizing activities by increasing insulin secretion, transduction, and β-cell function or by reducing inflammation and lipotoxicity.
Conclusions:
Incretin-based therapies, as modulators of oxidation and insulin resistance, may target the main pathophysiological factors of sarcopenia, thus providing a promising strategy for the treatment of this disease.
Insights
Incretin-based therapies show promise for treating sarcopenia by combating oxidative stress and improving insulin resistance, key factors in its development. These treatments may offer a new strategy for managing this age-related muscle-wasting disease.
Area of Science:
- Endocrinology
- Gerontology
- Metabolic Diseases
Background:
- Sarcopenia pathogenesis is linked to diabetes hallmarks, oxidative stress, and insulin resistance.
- Incretin-based therapies possess antioxidant and insulin-sensitizing properties.
- These properties suggest potential therapeutic benefits for sarcopenia.
Purpose of the Study:
- To review the role of oxidative stress and insulin resistance in sarcopenia.
- To explore the potential benefits of incretin-based therapies for sarcopenia treatment.
Main Methods:
- Literature search conducted using PubMed, Cochrane Library, and Google Scholar.
- Keywords related to sarcopenia, oxidative stress, insulin resistance, and incretin-based therapies were applied.
- Articles meeting selection criteria were identified for review.
Main Results:
- Incretin-based therapies demonstrate antioxidant effects by enhancing defense systems and reducing free radicals.
- These therapies improve insulin signaling, glucose homeostasis, and beta-cell function.
- They also exhibit insulin-sensitizing activities by reducing inflammation and lipotoxicity.
Conclusions:
- Incretin-based therapies modulate key factors in sarcopenia pathogenesis, including oxidation and insulin resistance.
- They represent a promising therapeutic strategy for sarcopenia.
- Targeting these pathophysiological mechanisms may effectively treat sarcopenia.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:23Dipeptidyl Peptidase 4 Inhibitors
01:06Oral Hypoglycemic Agents: Glinides
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Hypoglycemia and Glucagon